Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
J Vet Pharmacol Ther ; 29(4): 289-97, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16846466

ABSTRACT

Mepartricin is a semi-synthetic macrolide antibiotic developed as a drug for the treatment of benign prostatic hyperplasia (BPH) in human patients. In the present study, aged rats are used as an experimental model to evaluate the effects of mepartricin on circulating hormone concentrations and prostate receptor concentrations, to compare these possible effects with clinical findings observed in long-term treated dogs. Fifty-six aged male rats were randomly divided into four experimental groups treated orally with 0 (group 1), 2 mg (group 2), 5 mg (group 3) and 20 mg (group 4) mepartricin/kg of body weight. for 28 days respectively. Serum oestradiol and testosterone concentrations were measured by radio-immune-assays methods. Binding assays were used to measure the prostate concentrations of oestrogen receptors (ER), androgen receptors (AnR), alpha(1)-adrenergic receptor (alpha(1)-AR), and beta-adrenerergic receptor (beta-AR) subtypes. Mepartricin induced a significant reduction of prostate weight and serum oestradiol concentrations. Serum testosterone concentrations were unaffected. The treatment induced a significant down-regulation of ER concentrations (P < 0.05) and a significant up-regulation of AnR (P < 0.05) in rat prostate. Mepartricin induced a significant (P < 0.05) dose-dependent up-regulation of alpha(1)-AR and beta(2)-AR. In contrast, the concentration of beta(3)-ARs was significantly decreased (P < 0.05) in treated animals. The increase in prostate beta(2)-AR concentrations observed in subjects treated with mepartricin may be a favourable element in the evolution of BPH, because of the role exerted by these receptors in the control of prostatic smooth muscle relaxation. Curiously, beta(3)-AR concentrations were significantly reduced in treated animals. Data collected suggest that the prostatic beta-AR expression might be strongly influenced by oestrogen deprivation (mepartricin treatment); therefore, the combination of oestrogen suppression (mepartricin) and adrenergic suppression (alpha(1)-AR blockers) may be proposed as a possible nonhormonal therapeutic strategy for the treatment of benign prostatic hyperplasia in dogs.


Subject(s)
Mepartricin/pharmacology , Receptors, Adrenergic/drug effects , Administration, Oral , Aging , Animals , Disease Models, Animal , Dog Diseases/drug therapy , Dogs , Dose-Response Relationship, Drug , Drug Administration Schedule , Estradiol/blood , Male , Mepartricin/administration & dosage , Mepartricin/blood , Prostatic Hyperplasia/drug therapy , Prostatic Hyperplasia/veterinary , Rats , Testosterone/blood
2.
Bone ; 33(4): 567-74, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14555260

ABSTRACT

Several studies have shown that treatment with bisphosphonates can reduce the pain associated with different painful diseases. In a previous study we demonstrated that in mice two bisphosponates, clodronate and pamidronate, had an antinociceptive effect under acute conditions not related to bone processes, after in vein (iv) or intracerebroventricular (icv) injection. The present study tested the time-dependent antinociceptive action of clodronate and pamidronate in comparison with that of acetylsalicylic acid (ASA) and morphine after iv and icv injection using the tail-flick test in acute and chronic treatment. The effects of clodronate on other measures of animal behaviour were also evaluated. In the tail-flick test, administration of clodronate iv produced an antinociceptive effect that was greater than that of ASA and statistically significant up to 16 h; pamidronate iv showed a significant antinociceptive effect for only 6 h. Clodronate and pamidronate icv showed an increase in tail-flick latency time that was significant and lasted for 16 and 6 h, respectively, while morphine produced an antinociceptive effect for 24 h. In the test we found significant differences between male and female mice in the latency time values but not in the length of the analgesic effect. In the chronic treatment paradigm, clodronate produced a significant increase of the tail-flick latency after the first injection. The analgesic effect increased up to 50% after 5 days of treatment. Significant analgesic effects were still present after 3, 7, and 14 days from the end of treatment. Clodronate did not produce any significant behavioural effects in the Rota-rod test, pentobarbital-induced sleeping time, and locomotor activity cage. These data indicate that clodronate presents a central and peripheral prolonged antinociceptive effect, without any behavioural side effects.


Subject(s)
Analgesics, Non-Narcotic/pharmacology , Clodronic Acid/pharmacology , Analgesics, Non-Narcotic/administration & dosage , Animals , Aspirin/administration & dosage , Aspirin/pharmacology , Behavior, Animal/drug effects , Clodronic Acid/administration & dosage , Diphosphonates/administration & dosage , Diphosphonates/pharmacology , Female , Injections, Intravenous , Injections, Intraventricular , Male , Mice , Morphine/administration & dosage , Morphine/pharmacology , Pamidronate , Sex Characteristics , Time Factors
3.
Anesth Analg ; 97(2): 402-408, 2003 Aug.
Article in English | MEDLINE | ID: mdl-12873925

ABSTRACT

UNLABELLED: We determined the analgesic and antiinflammatory actions and the related acute mucosal gastric damage from the active S(+)-isomer ibuprofen (dexibuprofen), in comparison with those of the standard racemic formulation of ibuprofen in rodents. The antinociception was evaluated by hot-plate and tail-flick methods after IV and oral (PO) administration in mice and after PO administration in rats. S(+)-Ibuprofen was at least twice more potent than the ibuprofen racemic formulation. The antiinflammatory action of the test compound, assessed with the abdominal constriction test in mice (IV and PO) and with hind paw edema in rats (IV and PO), was found to be significantly more potent than that of ibuprofen after IV treatment in mice and PO administration in rats. Moreover, the test compound caused significantly less mucosal gastric damage than the racemic formulation administered at identical doses (50 mg/kg PO in rats). In conclusion, the S(+)-ibuprofen isomer was found to be more potent than the racemic formulation in analgesic and antiinflammatory tests and presented fewer gastric toxic effects. On the basis of the results of this work, we suggest that the administration of chemical entities, such as R(-)-ibuprofen, should be avoided if they are not essential for the anticipated therapeutic activity. IMPLICATIONS: Ibuprofen is a nonsteroidal antiinflammatory drug often prescribed as a racemic formulation. We studied the analgesic and antiinflammatory effects of the active S(+)-isomer. The S(+)-ibuprofen was found to be more potent than the racemic formulation and produced less acute gastric damage.


Subject(s)
Analgesia , Analgesics, Non-Narcotic/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Gastric Mucosa/pathology , Ibuprofen/therapeutic use , Inflammation/drug therapy , Analgesics, Non-Narcotic/toxicity , Animals , Anti-Inflammatory Agents, Non-Steroidal/toxicity , Carrageenan , Dose-Response Relationship, Drug , Drug Evaluation , Gastric Mucosa/drug effects , Ibuprofen/toxicity , Inflammation/chemically induced , Male , Mice , Mice, Inbred Strains , Pain Threshold , Rats , Rats, Sprague-Dawley
4.
J Antimicrob Chemother ; 49(2): 321-5, 2002 Feb.
Article in English | MEDLINE | ID: mdl-11815574

ABSTRACT

Venous tolerance of a new water soluble polyene antibiotic, SPK-843, in 5% glucose solution for infusion is low in laboratory animals. The use of Intralipid 10% emulsion was therefore proposed, in which the antibiotic remained chemically stable for at least 2 h in a mildly acid or nearly neutral environment and at concentrations of 0.1-0.5 mg/mL, producing no alterations in the emulsion structure. Tolerance was assessed through repeated infusions in the ear marginal vein of rabbits and was found much more satisfactory than the tolerance observed when the vehicle used was 5% glucose solution. The study of the effect of some variables (concentration, volume infused, dose per kg) on venous toxicity offered the possibility to plan optimal administration conditions of presumed therapeutic doses.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Fat Emulsions, Intravenous/administration & dosage , Polyenes/administration & dosage , Animals , Anti-Bacterial Agents/chemistry , Antifungal Agents/administration & dosage , Antifungal Agents/chemistry , Drug Evaluation, Preclinical/methods , Drug Evaluation, Preclinical/statistics & numerical data , Ear, External/blood supply , Infusions, Intravenous , Male , Polyenes/chemistry , Rabbits , Solubility , Veins/drug effects , Veins/physiology
5.
Pain ; 91(3): 269-275, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11275384

ABSTRACT

Bisphosphonates are analogues of inorganic pyrophosphate and are inhibitors of bone resorption. Many derivatives have been developed for the treatment of enhanced bone resorption; several reports reveal that treatment with bisphosphonates is able to reduce the pain associated with different painful diseases. This study tested the antinociceptive action of four bisphosphonates, clodronate, alendronate, pamidronate and etidronate, in comparison with that of morphine and acetylsalicylic acid using two algesimetric tests in mice, tail-flick and writhing tests. In the tail-flick test, after intravenous (i.v.) injection, a dose-dependent antinociception was present after pamidronate, clodronate and acetylsalicylic acid whereas etidronate and alendronate produced an analgesic effect only with the highest dose tested. We also studied the central effect of clodronate and pamidronate and, after intracerebroventricular injection, both bisphosphonates showed a dose-dependent antinociceptive effect. In the writhing test clodronate and pamidronate showed a statistically significant antinociceptive action after i.v. and intramuscular administration. To verify if clodronate and pamidronate could modulate the peripheral opioid receptors we evaluated the gastrointestinal transit time in mice, but we did not find any effect on the gastrointestinal motility. These data indicate that clodronate and pamidronate present a central and peripheral antinociceptive effect; however, the main mechanism cannot be determined from the present data. We discuss the possible pharmacological hypothesis to interpret the present results. The findings suggest a pharmacological role of the bisphosphonates in the modulation of antinociception even in acute conditions not related to accelerated osteolytic and inflammatory response, with a possible clinical application to control pain.


Subject(s)
Analgesics, Non-Narcotic/pharmacology , Anti-Inflammatory Agents/pharmacology , Clodronic Acid/pharmacology , Diphosphonates/pharmacology , Pain/drug therapy , Abdomen , Animals , Dose-Response Relationship, Drug , Etidronic Acid/pharmacology , Gastrointestinal Motility/drug effects , Male , Mice , Mice, Inbred Strains , Pain Measurement/drug effects , Pamidronate , Tail
6.
Chemotherapy ; 47(2): 77-85, 2001.
Article in English | MEDLINE | ID: mdl-11173807

ABSTRACT

Single- and multiple-administration trials in rats were performed in this study to assess the serum and tissue concentrations of SPK-843 (N-dimethylaminoacetyl-partricin A 2-dimethylaminoethylamide diascorbate), a new polyene antibiotic with a heptaene structure. A dose of 1.25 mg/kg (roughly 1 mg/kg of free base) by intravenous route was used both for the single- and multiple-administration trials. The single-administration trial was carried out in comparison with amphotericin B (AmB) at intravenous doses of 1 mg/kg. Plasma samples were drawn at intervals from 15 min to 96 h after injection. The elimination half-lives were 22.15 and 18.15 h, and the area under the curve to infinity (AUC(0-infinity)) values were 35.52 and 10.33 microg.h.ml(-1), respectively, for SPK-843 and AmB. Both drugs showed an extensive tissue distribution, with higher uptake by the kidneys, followed by the liver, spleen and lungs for SPK-843, and higher uptake by the spleen, followed by the lungs, liver and kidneys for AmB. The multiple-administration trial (1.25 mg/kg/day for 7 days) led to sustained serum and tissue concentrations. On the seventh day, the rats were bled at intervals from 5 min to 96 h after dosing. The serum elimination half-life and AUC(0-infinity) values were roughly twice those of the single-dose study (41.4 h and 72.1 microg.h.ml(-1), respectively). Also, the half-lifes and AUCs from 0 to infinity of tissues were greater than those in the single-dose trial.


Subject(s)
Antifungal Agents/pharmacokinetics , Polyenes/pharmacokinetics , Amphotericin B/pharmacokinetics , Animals , Antifungal Agents/administration & dosage , Area Under Curve , Half-Life , Injections, Intravenous , Kidney/metabolism , Liver/metabolism , Lung/metabolism , Male , Polyenes/administration & dosage , Rats , Rats, Sprague-Dawley , Spleen/metabolism , Tissue Distribution
7.
Chemotherapy ; 47(6): 387-95, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11786653

ABSTRACT

The pharmacokinetics and tissue distribution of three preparations of SPK-843 (N-dimethylaminoacetyl-partricin A 2-dimethylaminoethylamide diascorbate), a new polyene antibiotic with a heptaene structure, were compared in rats after a single 1.25 mg/kg intravenous administration. Blood and tissue samples were obtained at 0.25-96 h after injection. The serum pharmacokinetics of the three dosage forms of the antibiotic, A (5% glucose solution), B (10% lipid emulsion at pH 5.3) and C (10% lipid emulsion at pH 7.5), did not show large differences, the half-lives being 22.2, 26.5 and 23.2 h and the AUC(0-infinity) 35.5, 40 and 44.8 microg.h.ml(-1) for preparations A, B and C, respectively. The tissue uptake of the two lipid-based preparations, particularly the spleen uptake, was greater than that of the glucose preparation, suggesting an active role of the lipid vehicle in tissue distribution.


Subject(s)
Antifungal Agents/pharmacokinetics , Polyenes/pharmacokinetics , Animals , Antifungal Agents/administration & dosage , Area Under Curve , Chemistry, Pharmaceutical , Half-Life , Injections, Intravenous , Male , Polyenes/administration & dosage , Rats , Rats, Sprague-Dawley
8.
Chemotherapy ; 46(3): 153-9, 2000.
Article in English | MEDLINE | ID: mdl-10765028

ABSTRACT

Pharmacokinetics of a new semisynthetic polyene antibiotic (N-dimethylaminoacetyl-partricin A 2-dimethylaminoethylamide) in the form of its diaspartate salt (code SPA-S-753) was studied in rats and mice following intravenous injection and in rats following oral administration at different dose levels. In rats the urinary and biliary recovery after intravenous administration was also determined. Rats and mice received a single intravenous injection of 1.25 and 2.5 mg/kg of SPA-S-753 (about 1-2 mg/kg of free base) or 1 mg/kg of amphotericin B as reference drug. Blood samples were obtained at 5 min to 96 h after injection. The half-lives at the elimination phase in serum were 21.3, 26.5, 10.8 h in rats and 11.7, 13.7, 19.8 h in mice, respectively, for 1.25 and 2.5 mg/kg of SPA-S-753 and 1 mg/kg of amphotericin B. The values of AUC(0-infinity) for SPA-S-753 were about 5 times higher in rats and twice higher in mice than those for amphotericin B. Rats received also a single oral dose of 200 or 500 mg/kg of SPA-S-753. Serum samples were obtained at 0.5-96 h after dosing. The compound is poorly absorbed by the oral route. The mean cumulative urinary recovery of SPA-S-753 at 48 h after intravenous injection of 1.25 mg/kg in rats accounts only for 0.5% of the dose, while the cumulative recovery from the bile at 10 h after 2.5 mg/kg i.v. administration in rats accounts for 5.5% of the dose.


Subject(s)
Antifungal Agents/pharmacokinetics , Polyenes/pharmacokinetics , Administration, Oral , Amphotericin B/pharmacokinetics , Animals , Antifungal Agents/administration & dosage , Antifungal Agents/metabolism , Bile/metabolism , Injections, Intravenous , Male , Mice , Mice, Inbred Strains , Polyenes/administration & dosage , Polyenes/metabolism , Rats
9.
Farmaco ; 52(6-7): 449-56, 1997.
Article in English | MEDLINE | ID: mdl-9372597

ABSTRACT

The racemates and several enantiomers of 2-phenoxypropionic acids, bearing alkyl, acetyl, benzyl, benzoyl, phenyl, difluorophenyl, Cl, NO2 groups on the aromatic moiety, were investigated as potential analgesic-antiinflammatory drugs. The enantiomers, whose absolute configuration has been previously determined by us, were prepared by chiral resolution of the diastereoisomeric salts of the racemates with cynchonidine. The enantiomeric excess was determined by chiral chromatography. The chiroptical properties of the dextroisomers were investigated by CD. The pharmacological properties of the racemates and the enantiomers were monitored by analgesic-antiinflammatory activity tests as well as by gastrotolerability and acute toxicity tests. Some compounds were shown to be superior to ASA and ketoprofen because they have higher or similar analgesic properties, with less gastroulcerogenetic activity. Furthermore low acute toxicity was found for the compounds with high values of ED50. Correlations between the configuration of the enantiomers and their activity are not evident. For the most active compounds, the activity of one of the enantiomers is superior to that of the racemates. This is particularly true for (S)-3, (R)-15 and (S)-18.


Subject(s)
Analgesics/pharmacology , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Propionates/pharmacology , Analgesics/chemistry , Analgesics/toxicity , Animals , Anti-Inflammatory Agents, Non-Steroidal/chemistry , Anti-Inflammatory Agents, Non-Steroidal/toxicity , Circular Dichroism , Male , Mice , Molecular Conformation , Propionates/chemistry , Propionates/toxicity , Rats , Rats, Sprague-Dawley , Stomach/drug effects
10.
Biopharm Drug Dispos ; 14(2): 143-60, 1993 Mar.
Article in English | MEDLINE | ID: mdl-8453024

ABSTRACT

Six preparations were considered: three multiple unit dosage forms (micropellets in capsules) (D, E and G) and one matrix tablet (B) were experimental prolonged release formulations, two non-disintegrating tablets (A and C) were commercial products. The in vitro dissolution behaviour of the differing formulations was investigated using the USP XXII paddle apparatus. The in vivo study was effected on a panel of 12 healthy volunteers. The two commercial tablets (A and C) showed mean dissolution time (MDT) of 1.34 and 1.44 h and td of 91 and 92 min, respectively; for prolonged release formulations (B, E, D, and G) MDT ranged between 2.28 and 4.23 h and td between 149 and 291 min. The mean residence time (MRT) was 8.68 and 6.47 h for tablets A and C, respectively; it ranged between 9.62 and 10.24 h for the multiple unit formulations E, D, and G and was 11.27 h for matrix B. Formulation B also showed the higher apparent elimination half-life t1/2 (7.12 h), while apparent t1/2 for all the other formulations were very similar, ranging between 5.04 and 5.28 h. High variability between the various formulations was found for Cmax and AUC values, and no relationships could be established with the type of formulation. An in vitro/in vivo correlation was found for all the formulations examined on the basis of analogous parameters (MDT and MRT); (r = 0.83, p < 0.05). In a few cases the Wagner-Nelson deconvolution method was applied to individual plasma level versus time curves and the corresponding absorption curves were obtained. In these cases the in vitro/in vivo correlation was tested on the basis of the comparison of the in vivo absorption curves with the in vitro dissolution profiles. This was accomplished using the 'Levy's plot' (per cent released versus per cent absorbed) approach and provided further support for the correlation found.


Subject(s)
Diltiazem/administration & dosage , Diltiazem/pharmacokinetics , Adult , Biological Availability , Capsules , Chromatography, High Pressure Liquid , Delayed-Action Preparations , Diltiazem/blood , Humans , In Vitro Techniques , Tablets
11.
Eur J Clin Pharmacol ; 37(4): 419-21, 1989.
Article in English | MEDLINE | ID: mdl-2598977

ABSTRACT

The pharmacokinetics and bioavailability of suckable tablets and granules of N-acetylcysteine (NAC) have been compared after oral administration of 400 mg doses to 10 healthy volunteers. The oral bioavailability of the NAC tablets was 103%. In a multiple dosing study of the same tablets in the same subjects, a high maintenance plasma level of NAC was revealed.


Subject(s)
Acetylcysteine/pharmacokinetics , Acetylcysteine/administration & dosage , Administration, Oral , Adult , Biological Availability , Drug Compounding , Female , Humans , Male , Middle Aged , Tablets
12.
Mech Ageing Dev ; 47(1): 39-45, 1989 Jan.
Article in English | MEDLINE | ID: mdl-2542702

ABSTRACT

The effect of aging and subchronic treatment with acetyl-L-carnitine (50 mg/kg per day) was studied on mitochondrial bioenergetics and cholinergic metabolism in non-synaptic mitochondria and synaptosomes isolated from cerebral cortex, hippocampus and striatum of rats aged 4, 11 and 18 months. Respiratory activity and cytochrome oxidase specific activity were unaffected by aging in non-synaptic mitochondria. In synaptosomes, pyruvate dehydrogenase, choline acetyltransferase and acetylcholinesterase specific activity remained unchanged, but the high-affinity choline uptake decreased in cerebral cortex and striatum of 18-month-old rats. Acetyl-L-carnitine treatment increased the high-affinity choline uptake in cerebral cortex of 18-month-old rats. The treatment caused also an increase in cytochrome oxidase activity in all the three cerebral regions and in choline uptake in the hippocampus, parameters that were not directly affected by aging processes.


Subject(s)
Acetylcarnitine/pharmacology , Aging/metabolism , Brain/metabolism , Carnitine/analogs & derivatives , Choline/metabolism , Energy Metabolism , Acetylcholinesterase/metabolism , Aging/drug effects , Animals , Brain/drug effects , Choline O-Acetyltransferase/metabolism , Electron Transport Complex IV/metabolism , Male , Mitochondria/drug effects , Mitochondria/metabolism , Oxygen Consumption , Pyruvate Dehydrogenase Complex/metabolism , Rats , Rats, Inbred Strains , Synaptosomes/drug effects , Synaptosomes/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...